A Peptide Inhibitor of the Human Cytomegalovirus Core Nuclear Egress Complex

Area of Science:

• Virology
• Molecular Biology
• Drug Discovery

Background:

• Human cytomegalovirus (HCMV) replication requires nuclear egress, a process involving the core nuclear egress complex (NEC).
• The HCMV core NEC, a pUL50-pUL53 heterodimer, is a potential antiviral target.
• Previous studies identified a pUL53-derived peptide that inhibits pUL50-pUL53 interaction in vitro.

Purpose of the Study:

• To investigate the antiviral potential of a pUL53-derived peptide targeting the HCMV core NEC.
• To assess the peptide's ability to inhibit HCMV infection and core NEC formation in cells.
• To evaluate the efficacy of a cell- and nucleus-penetrating fusion peptide (NLS-CPP-Hook) derived from the pUL53 peptide.

Main Methods:

• In vitro characterization of a 29-mer peptide derived from pUL53.
• Assessment of peptide's effect on HCMV infection and core NEC formation in human foreskin fibroblast (HFF) cells.
• Design and testing of a fusion peptide (NLS-CPP-Hook) with translocation moieties for cellular and nuclear uptake.

Main Results:

• The pUL53-derived peptide inhibits the pUL50-pUL53 interaction and HCMV infection in cell culture.
• The peptide interferes with core NEC formation in HCMV-infected cells.
• The fusion peptide NLS-CPP-Hook demonstrates specific cellular and nuclear uptake in HFF cells and inhibits HCMV infection.

Conclusions:

• The pUL50-pUL53 interaction within the HCMV core NEC is a viable target for antiviral drug development.
• A peptide-based strategy can effectively inhibit HCMV replication by disrupting nuclear egress.
• The developed fusion peptide NLS-CPP-Hook shows promise as a therapeutic agent against HCMV infection.